First results of TURANDOT Trial

Professor Christoph Zielinski from the Comprehensive Cancer Centre, Vienna, Austria, presented the first efficacy results from the phase 3 study run by the Central European Cooperative Oncology Group (CECOG). The presentation was entitled the ‘capeciTabine and bevacizUmab Randomised Against avastiN anD taxOl Trial’ (TURANDOT). The study compared two bevacizumab-containing regimens as first-line therapy for HER2 negative metastatic breast cancer. Read more here.